Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
Fermenta now becomes one of the only two companies globally to hold a CEP for this variant of Vitamin D3
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
NewCo’s pipeline includes five investigational medicines
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
This year, the OCTF focused on preparing a white paper on oral cancer elimination in India and updating its annual consensus guidelines
Subscribe To Our Newsletter & Stay Updated